Drug Profile


Alternative Names: CHX 3107

Latest Information Update: 05 Feb 2008

Price : $50

At a glance

  • Originator Senju Pharmaceutical
  • Developer Senju Pharmaceutical; Toyama Chemical
  • Class Antiulcers; Benzopyrans; Eye disorder therapies
  • Mechanism of Action Immunosuppressants; Phospholipase A2 inhibitors; Reactive oxygen species inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Allergic conjunctivitis; Cerebral infarction; Lung transplant rejection; Reperfusion injury; Stroke

Most Recent Events

  • 05 Feb 2008 Discontinued - Phase-II for Stroke in Japan (unspecified route)
  • 05 Feb 2008 Discontinued - Phase-II for Reperfusion injury in USA (unspecified route)
  • 05 Feb 2008 Discontinued - Phase-II for Reperfusion injury in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top